Reuters -- Compugen Ltd announced the discovery and experimental validation of a new drug target for the treatment of a type of cancer, sending its shares up as much as 41 percent in pre-market trade.
Reuters -- Compugen Ltd announced the discovery and experimental validation of a new drug target for the treatment of a type of cancer, sending its shares up as much as 41 percent in pre-market trade.
